

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for October 2024

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Marcan Pharmaceuticals Inc.	MAR-Metformin XR	Glumetza	METFORMIN HCL	500 mg	ER tablet	02550504
Marcan Pharmaceuticals Inc.	MAR-Metformin XR	Glumetza	METFORMIN HCL	1000 mg	ER tablet	02550512
Pharmascience Inc.	Pms-Palbociclib	Ibrance	PALBOCICLIB	75 mg	tablet	02552124
Pharmascience Inc.	Pms-Palbociclib	Ibrance	PALBOCICLIB	100 mg	tablet	02552132
Pharmascience Inc.	Pms-Palbociclib	Ibrance	PALBOCICLIB	125 mg	tablet	02552140

Taro Pharmaceuticals Inc.	Taro-Palbociclib	Ibrance	PALBOCICLIB	75 mg	tablet	02547635
Taro Pharmaceuticals Inc.	Taro-Palbociclib	Ibrance	PALBOCICLIB	100 mg	tablet	02547643
Taro Pharmaceuticals Inc.	Taro-Palbociclib	Ibrance	PALBOCICLIB	125 mg	tablet	02547651
Jamp Pharma Corporation	Jamp Topiramate Tablets	Topamax	TOPIRAMATE	50 mg	tablet	02544377